Halozyme Therapeutics, Inc. vs. ImmunityBio, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$109.86 +2.73%
VS IBRXImmunityBio, Inc. Common Stock
$10.29 +10.83%
Halozyme Therapeutics, Inc. and ImmunityBio, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| HALO | IBRX | |
|---|---|---|
| Market Cap | $12.47 billion | $10.90 billion |
| Revenue (TTM) | $1.66 billion | — |
| Net Income (TTM) | $413.60 million | — |
HALO leads on 1 of 1 size & scale factors.
Valuation
| HALO | IBRX | |
|---|---|---|
| P/E Ratio | 32.12 | — |
| Price / Book | 86.87 | — |
| Price / Sales | 7.49 | — |
HALO and IBRX split the valuation factors evenly.
Profitability
| HALO | IBRX | |
|---|---|---|
| Net Margin | 24.86% | — |
| Return on Equity | 288.13% | — |
HALO and IBRX split the profitability factors evenly.
Risk & Sentiment
| HALO | IBRX | |
|---|---|---|
| Short Interest | 9.79% | 0.42% |
IBRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, IBRX overview, IBRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.